Wrocław, 02/14/2022

Current Report No 3/2022

Commencement of comparative research.

The Management Board of Genomtec S.A. based in Wrocław ("Issuer", "Company") hereby announces that the Company signed agreements with two Polish medical centers and CRO (Contract Research Organization) company based in France, providing professional services in conducting comparative testing and clinical studies ("Agreements"). The tests will be conducted on Genomtec®ID devices. The results obtained in the study will be the basis for registration of Genomtec®ID platform and Respiratory Panel (RP) 5-plex assay for CE-marking within the European Union planned for the middle of this year. The study has a multi-center character and will be conducted in Poland and France across a network of medical clinics, clinical laboratories and hospital settings.

The aim of the comparative study is to evaluate the performance of the Genomtec®ID diagnostic platform and the RP 5-plex test for the detection of viral and bacterial reasons causing respiratory infections. The RP 5-plex panel identifies 5 pathogens: Influenza A/B, RSV, SARS-CoV-2, *M.pneumoniae* and *C.pneumoniae* simultaneously in one single test. The results of these tests will be compared with reference methods of Real-Time (RT)-PCR to establish performance characteristics of the Genomtec®ID solution and use the data necessary for registration as a medical device for in-vitro diagnostics, in accordance with Directive 98/79/EC (IVD) in the European Union what the Company wants to achieve in the middle of this year.

Total remuneration under the Agreements, due to Polish medical centres and the French CRO, does not exceed 20% of the Company's balance sheet total value and may be further clarified upon receipt of the final study report. Statistical analysis of survey data under the Agreement will be conducted on samples collected in Poland and France. The agreements and the remuneration specified therein include, inter alia, such elements as:

- Collection of clinical samples from patients and their biobanking (where needed);
- Execution of a medical IVD diagnostic experiment on retrospective as well as prospective samples according to the Clinical investigation plan (experimental testing is carried onto the Genomtec® ID Diagnostic platform, whereas reference testing is carried out in the Central Laboratory);
- Manage and monitor the activities of the clinical sites;
- Statistical analysis for technical file
- Report generation and documentation for product registration of the reaction card and the analyzer – in the territory of the European Union in accordance with the

requirements of Directive 98 98/79/EC of the European Parliament and the Council – IVDD.

The commencement of comparative research is an important stage in the Issuer's key project and is a condition for the market authorization of the Company's flagship product therefore, in the opinion of the Management Board, this information meets the criteria of confidential information within the meaning of Article 17(1) MAR.